

The Medical Letter[®]

on Drugs and Therapeutics

Volume 67

June 9, 2025

ISSUE No.
1730

IN THIS ISSUE

In Brief: Prevention of Measlesp 94

Important Copyright Message

FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS

The Medical Letter, Inc. publications are protected by U.S. and international copyright laws. Forwarding, copying, or any distribution of this material without permission to a nonsubscriber is prohibited.

Sharing a password with a nonsubscriber or otherwise making the contents of this site available to third parties is prohibited.

By accessing and reading the attached content I agree to comply with U.S. and international copyright laws and these terms and conditions of The Medical Letter, Inc.

**For further information click: [Subscriptions](#), [Site Licenses](#), [Reprints](#)
or call customer service at: 800-211-2769**

The Medical Letter®

on Drugs and Therapeutics

Volume 67 (Issue 1730)

June 9, 2025

Take CME Exams

IN BRIEF

Prevention of Measles

According to the Centers for Disease Control (CDC), as of May 15 there have been 1024 confirmed cases of measles in the US in 2025; 11% of cases have resulted in hospitalization and 3 patients have died. The majority of cases (96%) have been in unvaccinated persons or in those whose vaccination history was unknown.¹

TRANSMISSION — The measles virus can be transmitted by direct contact with or airborne exposure to infectious droplets. Importation of measles by international travelers has led to outbreaks in the US, primarily in unvaccinated persons.

RECOMMENDATIONS — No antiviral drugs have been approved by the FDA for treatment or prevention of measles. The live-attenuated MMR (measles, mumps, rubella) vaccine [or the MMRV (measles, mumps, rubella, varicella) vaccine in children 12 months-12 years old] offers the best protection against measles; one dose is 93% and two doses are 97% effective in preventing infection.²

Children — The Advisory Committee on Immunization Practices (ACIP) currently recommends 2 lifetime doses of an MMR vaccine for most individuals; the first dose should be given at 12-15 months of age and the second at 4-6 years (3 months after first dose is an alternative). Infants 6-11 months old who will be traveling internationally should receive one early dose of MMR vaccine before travel followed by the routine 2-dose series after their first birthday.³ Due to current outbreaks in the US, some experts are recommending that infants 6-11 months old who live in or are traveling to an area in the US where an outbreak is occurring also receive an early dose.³

Adults — Adults born in the US before 1957 (1970 in Canada) can be considered immune to measles, mumps, and rubella. Adults who lack evidence of

immunity (documentation of vaccination, laboratory evidence of immunity, previously vaccinated with the killed [or an unknown] measles vaccine used from 1963 to 1967) should receive one dose of MMR vaccine. Two doses of the vaccine, separated by at least 28 days, are recommended for adults without evidence of immunity who are at high risk of exposure to or transmission of measles or mumps, including students in postsecondary educational institutions, international travelers, and household contacts of immunocompromised persons.^{4,5} Healthcare workers of any age should be evaluated for evidence of immunity.

CONTRAINDICATIONS TO VACCINATION — Because MMR is a live vaccine, it is contraindicated for use in pregnant women and in adults with severe immunodeficiency. The vaccine should not be given to persons with a history of anaphylaxis to neomycin (*M-M-R II* and *Priorix*) or hypersensitivity to gelatin (*M-M-R II*).

VACCINE ADVERSE EFFECTS — Pain and erythema at the injection site, fever, rash, and transient arthralgia are common following MMR vaccination. Few adverse events have been reported with a third dose of MMR vaccine. Anaphylactic reactions and thrombocytopenic purpura have occurred rarely following MMR vaccination.⁴ ■

1. CDC. Measles cases and outbreaks. May 15, 2025. Available at: <https://bit.ly/42lrS0S>. Accessed May 16, 2025.
2. CDC. Measles vaccination. January 17, 2025. Available at: <https://bit.ly/3RtNijK>. Accessed May 16, 2025.
3. B Rader et al. Revising US MMR vaccine recommendations amid changing domestic risks. *JAMA* 2025; 333:1201.
4. HQ McLean et al. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep* 2013; 62(RR-4):1.
5. E Krow-Lucal et al. Measles, mumps, rubella vaccine (PRIORIX): recommendations of the Advisory Committee on Immunization Practices – United States, 2022. *MMWR Morb Mortal Wkly Rep* 2022; 71:1465.

PRESIDENT: Mark Abramowicz, M.D.; **VICE PRESIDENT, EDITOR IN CHIEF:** Jean-Marie Pflomm, Pharm.D.; **ASSOCIATE EDITORS:** Susan M. Daron, Pharm.D., Amy Faucard, MLS, Corinne Z. Morrison, Pharm.D., Michael P. Viscusi, Pharm.D. **CONSULTING EDITORS:** Joanna Esterow, PA-C, Mordechai Sacks, DMSc, PA-C, Brinda M. Shah, Pharm.D., F. Peter Swanson, M.D.

CONTRIBUTING EDITORS: Carl W. Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Ericka L. Crouse, Pharm.D., B.C.P.P., C.G.P., F.A.S.H.P., F.A.S.C.P., Virginia Commonwealth University; Vanessa K. Dalton, M.D., M.P.H., University of Michigan Medical School; Eric J. Epstein, M.D., Albert Einstein College of Medicine; David N. Juurlink, BPhm, M.D., Ph.D., Sunnybrook Health Sciences Centre; Richard B. Kim, M.D., University of Western Ontario; Sandip K. Mukherjee, M.D., F.A.C.C., Yale School of Medicine; Dan M. Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K. Schaefer, M.D., M.P.H., Harvard Medical School; Arthur M. F. Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell University

MANAGING EDITOR AND DIRECTOR OF CONTENT OPERATIONS: Susie Wong; **EDITORIAL ASSISTANT:** Karrie Ferrara

FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; **EXECUTIVE DIRECTOR OF SALES:** Elaine Reaney-Tomaselli

EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F. Valentino; **INTERIM PUBLISHER:** Jean-Marie Pflomm, Pharm.D.

Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.

Copyright and Disclaimer: The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug prescribing recommendations. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants. The Medical Letter, Inc. does not sell advertising or receive any commercial support. No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing. The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.

Subscription Services

Address:

The Medical Letter, Inc.
2 Madison Ave, Ste 211
Larchmont, NY 10538
www.medicalletter.org

Customer Service:

Call: 800-211-2769 or 914-235-0500
Fax: 914-632-1733
E-mail: custserv@medicalletter.org

Permissions:

To reproduce any portion of this issue,
please e-mail your request to:
permissions@medicalletter.org

Subscriptions (US):

1 year – \$179; \$65 per year
for students, interns, residents,
and fellows in the US and Canada.
Reprints – \$45 per issue or article

Site License Inquiries:

E-mail: SubQuote@medicalletter.org
Call: 800-211-2769
Special rates available for bulk
subscriptions.

Get Connected:



Copyright 2025. ISSN 1523-2859

